Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olaptesed pegol + bevacizumab
- Development stage
- Unknown
- Lead developer
- TME Pharma
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Olaptesed pegol + bevacizumab is a combination therapy under investigation for glioblastoma. Olaptesed pegol (NOX-A12) is a PEGylated antisense oligonucleotide that acts as a selective inhibitor of CXCL12 (stromal cell-derived factor 1), disrupting tumor-supporting microenvironments and impeding cancer cell migration, proliferation, and immune evasion. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thus inhibiting tumor angiogenesis. As a combination with radiotherapy, this regimen showed significantly improved median overall survival and response rates compared to standard of care in newly diagnosed, chemotherapy-resistant glioblastoma with measurable residual tumor after surgery. TME Pharma is the developer of olaptesed pegol and the sponsor of clinical trials. Bevacizumab is developed and manufactured by Genentech/Roche.
- Other names
- olaptesed pegol + AvastinNOX-A12 + bevacizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)CXCL12 (C-X-C motif chemokine ligand 12)
Beyond the preview
Go deeper on olaptesed pegol + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olaptesed pegol + bevacizumab.